NYSE · COR
Cencora, Inc.
Healthcare · Medical - Distribution
$309.05▼ 0.24% ($0.73)at close
As of 4:00 PM ET
Market cap
$60.13B
P/E
Valuation
Cash-flow DCF
Verdict: fairly priced. Price above Base.
The price holds with free cash flow shrinking 0.6% a year for 5 years. Our scenarios assume −17.5–12.5%.
Its past 10 years averaged −2.5% a year.
Value per share
Base case
$278.58
Price used $309.05 is 11% above this
USD · TTM ending Jun 30, 2026 · Price Oct 2, 8:00 PM UTC
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
CapEx normalization ceiling applied: historical capex ratio was set at smaller revenue scale. Capped at 2× TTM capex.
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Free cash flow each value needs
Free cash flow today $3.6B. The price needs $4.1B by 2036. Base case: $3.7B. At its recent pace: $2.8B. Bear to Bull: $1.6B to $9B.
Free cash flow today $3.6B. The price needs $4.1B by 2036. Base case: $3.7B. At its recent pace: $2.8B. Bear to Bull: $1.6B to $9B.
Free cash flow in 2036
today $3.6B
+$388Mmore than the Base case · 1.1×
Value per share · Base case
$278.58
Price $309.05
11% above this
- Stage 1 growth, yrs 1–5
- −2.5%
- Stage 2 growth, yrs 6–10
- 3.5%
- Discount rate
- 7.6%
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
CapEx normalization ceiling applied: historical capex ratio was set at smaller revenue scale. Capped at 2× TTM capex.
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
USD · TTM ending Jun 30, 2026 · Price Oct 2, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 0.64% over the last year. Revenue grew 5.09% over the trailing twelve months. Operating margin moved from 1.09% to 1.3%. Free cash flow grew 255.65% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 1.3%. A decisive move in revenue — currently up 5.09% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets.
Market multiples
Stock splits
Every 1 shares became 10
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
33
Buy
12
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est $4.54 · Revenue est $87.98B
View
Institutional Sentiment
Cencora, Inc. · COR
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.